This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-102 were previously canceled.

1 ~~103~~. (Currently Amended) A pharmaceutical formulation for delivery of a mixture of amphetamine base salts effective to treat ADHD in a human patient comprising:

an immediate release dosage form that provides immediate release upon oral administration to said patient;

a delayed enteric release dosage form that provides delayed release upon oral administration to said patient; and

a pharmaceutically acceptable carrier;

wherein said amphetamine base salts comprise dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate;

wherein said pharmaceutical ~~composition~~ formulation is sufficient to maintain an effective level of amphetamine base salts in the patient over the course of at least 8 hours without further administration of amphetamine base salt, and the peak plasma concentration of amphetamine base salts reached after release of said delayed enteric release dosage form exceeds the peak plasma concentration previously reached after release of said immediate release dosage form; and

wherein said pharmaceutical formulation, when containing ~~composition produces~~ about a total dose of 20 mg, will produce in a human individual a plasma concentration versus time curve (ng/ml versus hours) having an area under the curve (AUC) of about 467 to about 714 ng hr/ml~~, for about a 20 mg total dose, or an AUC proportional thereto for a total dose other than about 20 mg~~.

2 ~~104~~. (Currently Amended) A formulation of claim 1 ~~105~~ wherein said plasma concentration curve has a maximum concentration (C_{max}) of about 22.5 to about 40 ng/ml for

about a ~~10 mg~~ total dose ~~in each of said dosage forms, or a C_{max} proportional thereto for a dose in each of said dosage forms other than about 10 mg~~ of 20 mg.

3 2
~~105.~~ (Previously Added) A formulation of claim ~~104~~ wherein the time after said oral administration to reach said C_{max} value is about 7 to about 10 hours.

4 1
~~106.~~ (Previously Added) A formulation of claim ~~103~~ wherein the time after said oral administration to reach maximum concentration of said plasma concentration curve is about 7 to about 10 hours.

5 2 3 4
~~107.~~ (Previously Added) A formulation of claim ~~104~~, ~~105~~ or ~~106~~ wherein said AUC is about 714 ng hr/ml.

6 3
~~108.~~ (Previously Added) A formulation of claim ~~105~~ wherein said AUC is about 714 ng hr/ml, the time after said oral administration to reach said C_{max} value is about 7 hours and C_{max} is about 40 ng/ml.

7 2
~~109.~~ (Previously Added) A formulation of claim ~~104~~ wherein C_{max} is about 40 ng/ml.

8 3 4
~~110.~~ (Previously Added) A formulation of claim ~~105~~ or ~~106~~ wherein said time is about 7 hours.

9 1-4 6 7
~~111.~~ (Currently Amended) A formulation of one of claims ~~103~~-~~106~~, ~~108~~ or ~~109~~ wherein said salts are contained in about equal amounts within each of said dosage forms ~~and the total amphetamine salt amount in each of said dosage forms is about the same~~.

10 1-4 6 7
~~112.~~ (Previously Added) A formulation of one of claims ~~103~~-106, ~~108~~ or ~~109~~ wherein said delayed enteric release dosage form comprises a coating of a thickness of at least 20 μm which comprises dried about 30% (dry substance) aqueous dispersion of an anionic

F

copolymer based on methacrylic acid and acrylic acid ethyl ester, said coating being soluble at a pH of about 5.5 upwards.

11 10
~~13~~. (Previously Added) A formulation of claim ~~12~~ wherein said thickness is at least 25 μm.

12
~~14~~. (Previoulsy Added) A pharmaceutical formulation for delivery of a mixture of amphetamine base salts effective to treat ADHD in a human patient comprising:

71 cont

an immediate release dosage form that provides immediate release upon oral administration to said patient;

a delayed enteric release dosage form that provides delayed release upon oral administration to said patient, wherein said enteric release dosage form comprises a coating of a thickness of at least 20 μm which comprises dried aqueous dispersion of an anionic copolymer based on methacrylic acid and acrylic acid ethyl ester, said coating being soluble at a pH of about 5.5 upwards; and

a pharmaceutically acceptable carrier;

wherein said amphetamine base salts comprise dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate and amphetamine sulfate;

wherein said pharmaceutical formulation is sufficient to maintain an effective level of amphetamine base salts in the patient over the course of at least 8 hours without further administration of amphetamine base salt, and the peak plasma concentration of amphetamine base salts reached after release of said delayed enteric release dosage form exceeds the peak plasma concentration of said salts previously reached after release of said immediate release dosage form.

13 12
~~15~~. (Previously Added) A formulation of claim ~~14~~ wherein said thickness is at least 25 μm.

F

14
~~116~~. (Previously Added) A formulation of claim 12, wherein said dried aqueous dispersion of an anionic copolymer is a dried about 30% (dry substance) aqueous dispersion of an anionic copolymer.

15
~~117~~. (Newly Added) A formulation of claim 1 formulated for a total dose of 20 mg.

16
~~118~~. (Newly Added) A formulation of claim 2 formulated for a total dose of 20 mg.

17
~~119~~. (Newly Added) A formulation of claim 1 formulated for a total dose different from about 20 mg and having an AUC proportional to said 20 mg AUC.

18
~~120~~. (Newly Added) A formulation of claim 2 formulated for a total dose different from about 20 mg and having a C_{max} proportional to said 20 mg C_{max}.